CytomX Therapeutics, Inc.

CytomX Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative drug therapies aimed primarily at oncology. The company's core mission is to redefine cancer treatment through its proprietary Probody technology platform, which enables targeting of potent anti-cancer therapies directly to tumors, thereby minimizing damage to healthy tissue. This approach aims at improving the safety and efficacy profiles of existing cancer drugs. CytomX Therapeutics is deeply involved in research collaborations with major pharmaceutical companies seeking to enhance drug targeting and to bring transformative treatment options to patients with unmet medical needs. Operating in the highly volatile and research-intensive biopharmaceutical sector, the company's activities have significant implications for cancer treatment regimens and methods. Founded in 2008 and headquartered in South San Francisco, California, CytomX stands out in the market for its commitment to pioneering antibody-based therapies, contributing to the evolving landscape of cancer treatment through advanced clinical investigations and strategic partnerships.